Local Anesthesia and Tuberculin Skin Test in Infants and Children
Recruitment status was Not yet recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The use of local anaesthesia efficiently reduces pain due to needle puncture. However, when tuberculin skin test is performed it is the skin reaction to tuberculin injection that is studied. It is a quantitative skin reaction measured in millimiters. From the study of literature it is not known whether local anaesthetic modify skin reaction to tuberculin. Therefore, before recommending the use local anaesthesia for tuberculin intradermal injection we have to rule out a potential effect of local anaesthetic on the result of the test. This is particularly important in children, since there are more sensitive to pain than adults
| Condition | Intervention |
|---|---|
|
Tuberculosis |
Drug: lidocaine / Prilocaine |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Single Blind Primary Purpose: Treatment |
| Official Title: | Local Anesthesia Effect on Tuberculin Skin Test Results in Infants and Children |
- Measurement of tuberculin skin tests reaction performed with and without
- local anaesthesia, in a child (intra subject reproducibility)
- influence of local anaesthesia use, on tuberculin skin test interpretation
- between observer reproducibility
- pain evaluation in child over 5 years of age between tuberculin skin tests performed with and without local anaesthesia
- relationship between local anaesthesia use and failure to perform a correct intradermal injection
- local tolerance to lidocaine / prilocaine
| Estimated Enrollment: | 60 |
Eligibility| Ages Eligible for Study: | 1 Month to 15 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
hospitalized or non hospitalized infant or child (3 months-15 years)requiring a tuberculin skin test, in our hospital. hospitalized 1 to 3 months old infants requiring a tuberculin skin test, in our hospital.
-
Exclusion Criteria:
- child with contra indication to the use of Lidocaine / prilocaine
- child with evolutive dermatitis on forearms
- premature or newborn (less than 1 month of age)
- infants (1 - 24 months of age)who has yet received repeated local anaesthesia (at least 2)during the 24 previous hours
- infants (1 - 24 months of age)who is treated with a drug that could enhance the risk of methhaemoglobinemia
- child with previous evere local reaction to tuberculin injection (necrosis,ulceration)
- child with history of tuberculosis disease
- child with hepatic failure
- parents or the child himself if lod enough, have not given their agreement for the study
Contacts and Locations| Contact: Nicole Beydon, MD | +33 140 032 000 | nicole.beydon@rdb.aphp.fr |
| Contact: Estelle Marcault, ARC | +33 140 256 252 | estelle.marcault@bch.aphp.fr |
| France | |
| Robert Debré Hospital | Active, not recruiting |
| Paris, France, 75019 | |
| Principal Investigator: | Nicole Beydon, MD | APHP |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00309673 History of Changes |
| Other Study ID Numbers: | CRC05001 |
| Study First Received: | March 31, 2006 |
| Last Updated: | March 31, 2006 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Keywords provided by Assistance Publique - Hôpitaux de Paris:
|
tuberculosis, tuberculin, childhood, pain |
Additional relevant MeSH terms:
|
Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections Anesthetics Prilocaine Lidocaine EMLA Central Nervous System Depressants |
Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Anesthetics, Local Sensory System Agents Peripheral Nervous System Agents Anti-Arrhythmia Agents Cardiovascular Agents Anesthetics, Combined |
ClinicalTrials.gov processed this record on June 18, 2013